Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy h...

ver descrição completa

Detalhes bibliográficos
Autores: Driessen, Julia, Wit, Fer Der, Herrera, Alex F., Zinzani, Pier Luigi, LaCasce, Ann S., Cole, Peter D., Moskowitz, Craig H., García-Sanz, Ramón, Fuchs, Michael, Müller, Horst, Borchmann, Peter, Santoro, Armando, Schöder, Heiko, Zijlstra, Josee M., Kersten, Marie José
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/380488
Acesso em linha:http://hdl.handle.net/10261/380488
Access Level:Acceso aberto
Palavra-chave:Clinical Trials and Observations
Lymphoid Neoplasia
id ES_02a85dc4df0d9e29dc6adcb30b8a0b63
oai_identifier_str oai:digital.csic.es:10261/380488
network_acronym_str ES
network_name_str España
repository_id_str
spelling Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysisDriessen, JuliaWit, Fer DerHerrera, Alex F.Zinzani, Pier LuigiLaCasce, Ann S.Cole, Peter D.Moskowitz, Craig H.García-Sanz, RamónFuchs, MichaelMüller, HorstBorchmann, PeterSantoro, ArmandoSchöder, HeikoZijlstra, Josee M.Kersten, Marie JoséClinical Trials and ObservationsLymphoid NeoplasiaSeveral single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score–matched analysis encompassing individual patient data from 10 clinical trials to evaluate the impact of BV in transplant-eligible patients with R/R cHL. We included 768 patients, of whom 386 were treated with BV with or without chemotherapy (BV cohort), whereas 382 received chemotherapy alone (chemotherapy cohort). Propensity score matching resulted in balanced cohorts of 240 patients each. No significant differences were observed in pre-ASCT complete metabolic response (CMR) rates (P = .69) or progression free survival (PFS; P = .14) between the BV and chemotherapy cohorts. However, in the BV vs chemotherapy cohort, patients with relapsed disease had a significantly better 3-year PFS of 80% vs 70%, respectively (P = .02), whereas there was no difference for patients with primary refractory disease (56% vs 62%, respectively; P = .67). Patients with stage IV disease achieved a significantly better 3-year PFS in the BV cohort (P = .015). Post-ASCT PFS was comparable for patients achieving a CMR after BV monotherapy and those receiving BV followed by sequential chemotherapy (P = .24). Although 3-year overall survival was higher in the BV cohort (92% vs 80%, respectively; P < .001), this is likely attributed to the use of other novel therapies in later lines for patients experiencing progression, given that studies in the BV cohort were conducted more recently. In conclusion, BV with or without salvage chemotherapy appears to enhance PFS in patients with relapsed disease but not in those with primary refractory cHL.This work was financially supported by SHOW (Dutch Foundation of hemato-oncological research http://www.steunhematologie.nl/), which is a nonprofit donation fund of Amsterdam UMC.Peer reviewedAmerican Society of HematologyAmsterdam University FundConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/380488reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1182/bloodadvances.2023012145Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3804882026-05-22T06:33:51Z
dc.title.none.fl_str_mv Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
title Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
spellingShingle Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
Driessen, Julia
Clinical Trials and Observations
Lymphoid Neoplasia
title_short Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
title_full Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
title_fullStr Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
title_full_unstemmed Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
title_sort Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
dc.creator.none.fl_str_mv Driessen, Julia
Wit, Fer Der
Herrera, Alex F.
Zinzani, Pier Luigi
LaCasce, Ann S.
Cole, Peter D.
Moskowitz, Craig H.
García-Sanz, Ramón
Fuchs, Michael
Müller, Horst
Borchmann, Peter
Santoro, Armando
Schöder, Heiko
Zijlstra, Josee M.
Kersten, Marie José
author Driessen, Julia
author_facet Driessen, Julia
Wit, Fer Der
Herrera, Alex F.
Zinzani, Pier Luigi
LaCasce, Ann S.
Cole, Peter D.
Moskowitz, Craig H.
García-Sanz, Ramón
Fuchs, Michael
Müller, Horst
Borchmann, Peter
Santoro, Armando
Schöder, Heiko
Zijlstra, Josee M.
Kersten, Marie José
author_role author
author2 Wit, Fer Der
Herrera, Alex F.
Zinzani, Pier Luigi
LaCasce, Ann S.
Cole, Peter D.
Moskowitz, Craig H.
García-Sanz, Ramón
Fuchs, Michael
Müller, Horst
Borchmann, Peter
Santoro, Armando
Schöder, Heiko
Zijlstra, Josee M.
Kersten, Marie José
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Amsterdam University Fund
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Clinical Trials and Observations
Lymphoid Neoplasia
topic Clinical Trials and Observations
Lymphoid Neoplasia
description Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score–matched analysis encompassing individual patient data from 10 clinical trials to evaluate the impact of BV in transplant-eligible patients with R/R cHL. We included 768 patients, of whom 386 were treated with BV with or without chemotherapy (BV cohort), whereas 382 received chemotherapy alone (chemotherapy cohort). Propensity score matching resulted in balanced cohorts of 240 patients each. No significant differences were observed in pre-ASCT complete metabolic response (CMR) rates (P = .69) or progression free survival (PFS; P = .14) between the BV and chemotherapy cohorts. However, in the BV vs chemotherapy cohort, patients with relapsed disease had a significantly better 3-year PFS of 80% vs 70%, respectively (P = .02), whereas there was no difference for patients with primary refractory disease (56% vs 62%, respectively; P = .67). Patients with stage IV disease achieved a significantly better 3-year PFS in the BV cohort (P = .015). Post-ASCT PFS was comparable for patients achieving a CMR after BV monotherapy and those receiving BV followed by sequential chemotherapy (P = .24). Although 3-year overall survival was higher in the BV cohort (92% vs 80%, respectively; P < .001), this is likely attributed to the use of other novel therapies in later lines for patients experiencing progression, given that studies in the BV cohort were conducted more recently. In conclusion, BV with or without salvage chemotherapy appears to enhance PFS in patients with relapsed disease but not in those with primary refractory cHL.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/380488
url http://hdl.handle.net/10261/380488
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1182/bloodadvances.2023012145
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Society of Hematology
publisher.none.fl_str_mv American Society of Hematology
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402669824606208
score 15,811543

Registros relacionados